Velzatinib (IDRX-42, GSK6042981)
StrateGIST 1
GSK · Phase 1 · Active, not recruiting · Enrollment 276
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Velzatinib 300 mg tablet (or 400 mg capsule), 2L | 2L advanced GIST (n = 46) | 300 mg | Single arm | n/r | median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025objective response rate: 35%, cutoff 12.15.2025 |
| Velzatinib, 1L | 1L advanced GIST (n = 18) | 300 mg | Single arm | n/r | unconfirmed objective response rate: 61%, median follow up 6.4 months |